ABSTRACT
INTRODUCTION
Breast cancer is the most common malignancy threatening the health and life of women and its incidence has increased in both developed and developing countries 1 . Biologic mechanisms leading to the development of breast cancer are not clearly understood, but the role of cytokines in cancer immunity and carcinogenesis has been well established 2 . Cytokine involved in different physiologic and pathophysiologic processes such as inflammation, bone metabolism, synthesis of C-reactive protein, and carcinogenesis 3 . IL-6 has also been shown to inhibit the growth of various breast cancer cell lines 4 , shows antiadhesive effects 5 , and modulates the estrogen and progesterone receptors content of these cells 6 . IL-6 is thought to increase the activity of the 17-hydroxysteroid dehydrogenase, which converts estrone to estradiol, a process that may contribute to the increased concentration of estrogen around breast tumors. Furthermore, IL-6 has been shown to be involved in intercellular signaling between mesenchyme and breast cancer epithelium. These findings from in vitro studies extend to human breast cancer as elevated serum IL-6 levels were found to be independent prognosticators 7, 8 . The human IL-6 gene (IL6) is mapped to chromosome 7p21-24 with an upstream promoter containing 303 bp 9 . The common _174 G/C IL6 polymorphism has also been shown to influence in vivo protein expression by reducing transcription rates
.
The data on the _174 G/C IL6 polymorphism in breast cancer are controversial
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reported that the presence of the IL6 polymorphism was associated with an improved outcome in high-risk breast cancer, whereas
12
showed that the IL6 polymorphism was predictive of an aggressive breast cancer phenotype.
As a multifunctional Th2-cytokine with both immunosuppressive and antiangiogenic functions, interleukin-10 (IL-10) may have both tumorpromoting and tumor-inhibiting properties
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. G→A polymorphism, the polymorphic site was amplified with primers:
SUBJECTS & METHODS
Forward (F) (5′- AGCAACACTCCTCGTCGCAAC- 3′), Reverse (R1) (5′- CCTATCCCTACTTCCCCC-3′) specific for G or Reverse (R2) (5′- CCTATCCCTACTTCCCCT-3′) specific for A
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. For PCR, the following procedure was used: 30 cycles of 94 °C for 30 seconds, 60 °C for 60 seconds and 72 °C for 60 seconds. The PCR amplification was completed by a final extension at 72 °C for 6 minutes. The amplification yields a product 179 bp when electrophoresed on 3 % agarose and stained with ethidium bromide, and visualized under UV light. (Fig 1 & 2 
RESULTS
The demographics of cases and control enrolled in this study regarding age of menarche and menopausal status in both groups, Also, tumor characters including ER and PR expression, LN involvement, and tumor size and grade are summarized in Table (1) . There were statistically significant decrease in the age of menarche in the patients with breast cancer when compared with normal individuals but no significant difference in menopausal status between the studied groups (p = 0.02, p > 0.05 respectively).
The result of PCR determination of IL-6 -174 G→C genotypes in the studied groups, shown in table (2), revealed significant association in CC genotype frequency in patients with breast cancer when compared with normal individuals (p = 0.01). Also, there were significant association in C allele frequency in patients with breast cancer when compared with normal individuals (p = 0.01).
The Analysis of association between IL-6 -174 G→C genotypes and clinicopathological features of breast cancer patients, presented in Table  ( 3), revealed no association between IL-6 -174 G→C genotypes and ER expression, PR expression, tumor size, and grade of the tumor. LN involvement was significantly higher in patients with breast cancer who are carriers of CC genotype when compared with patients with breast cancer who are carriers of GG and GC genotypes (p = 0.01).
The result of PCR determination of IL-10
G→A genotypes in the studied groups revealed that, there was no significant difference in IL-10 -1082
G→A genotypes frequency (GG, GA and AA) in patients with breast cancer when compared with normal individuals (p = 0.99) as shown in Table (4). The Analysis of association between IL-10 1082 G→A genotypes and clinicopathological features of breast cancer patients, shown in Table  ( Table ( 
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. The -174G/CIL-6 polymorphism has been reported to influence plasma concentrations of the corresponding cytokine in response to different inflammatory stimuli. In this connection it has been studied for associations with many inflammatory and neoplastic diseases.
Several investigators observed significant racial, ethnical and populational difference in the frequencies of the -174G/C-alleles, underlying the importance of a local reference population when evaluating the clinical relevance of this polymorphism 28 . To the best of our knowledge, this is a first report on the IL-6 -174G/C polymorphism in the Egyptian population.
With respect to the -174 G/C IL6 polymorphism, this study provides data with respect to a significant association between the IL6 polymorphism CC genotype, C allele, and breast cancer.
As previously published for other malignancies
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, the -174 G/C IL6 polymorphism likely is important for carcinogenesis. The -174 G/C IL6 polymorphism is known to reduce gene transcription rate subsequently reducing protein levels. IL-6 is known to inhibit tumor cell growth. Therefore, women with decreased protein expression are at an increased risk for developing breast cancer.
The results of this study are in accordance with 30 , who found an association of the -174 G/C IL6 polymorphism with breast cancer susceptibility in Caucasian females. In that study, the carriers of the Callele had an increased risk for breast cancer in an allele dose-dependent fashion. Also, Iacopetta et al., 12 showed that the IL6 polymorphism was predictive of an aggressive breast cancer phenotype. However, Balasubramanian et al., 31 showed that the IL6 -174G/C polymorphism was not associated with either breast cancer risk or severity and prognosis.
Litovkin et al., 28 failed to find such association of the -174 G/C IL6 polymorphism with breast cancer susceptibility in the Ukrainian population.
Their observations support the suggestion that the -174G/C polymorphism in the IL-6 gene is not a risk factor of major importance for breast cancer, although it may possibly affect to some extent the severity of the disease. The presence of the -174 G/C IL6 polymorphism increases the risk of breast cancer in a dose dependent fashion.
We also, found that patients carrying IL6 -174 CC genotype were correlated with higher LN involvement (p=0.01) of breast cancer at the time of diagnosis compared with others. The findings suggest that the IL6 -174CC genotype might be adverse prognostic factors in breast cancer in Egyptian women. However, the study from the European Caucasian women showed that the homozygosity for the -174 C allele was significantly associated with poor histological grade and with ductal histology, and association with larger tumor size and low estrogen receptor content 12 . This case-control study evaluated the association between the polymorphisms of the IL-10 promoter and breast cancer in Egyptian population. The data did not show significant differences in allele and genotypes frequencies of IL-10 -1082(G→A) polymorphism between breast cancer patients and healthy controls. In concordance with this study, many authors 2,30-32 , reported that there were no apparent relationship of the IL-10 gene promoter polymorphisms with the risk of breast cancer. However, these results are not consistent with the study from the Italian population showed that the IL-10 -1082AA genotype was correlated with a marked increase in breast cancer risk 34 . Although it is difficult to determine the reasons behind the contradictory results in these studies, the different genetic background of study population may be one of the main factors.
We also, found that patients carrying IL-10 -1082AA were correlated with increased tumor size only, but not LN involvement and higher tumor stage of breast cancer at the time of diagnosis. However, the study from the Chinese Han women showed that the IL-10 -1082AA genotype was correlated with higher LN involvement and higher tumor stage of breast cancer 32 which may be due to different populations.
IL-10 is a multifunctional cytokine with both immunosuppressive and antiangiogenic functions, which may play varied roles in the pathogenesis and development of breast cancer. Although the genetic control of IL-10 expression is not clearly understood yet, polymorphisms in promoter have been reported to determine interindividual differences in IL-10 production 17, 35 .
CONCLUSION:
The homozygous CC genotype of the IL-6 -174 G→ C, but not IL-10 -1082(G→A) genotype was associated with breast cancer in Egyptian women. Also, IL6 -174 CC genotype was correlated with LN involvement in patients with breast cancer and IL-10 -1082AA genotype was correlated with increased tumor size in patients with breast cancer. 
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